Journal Article

Extracorporeal photopheresis (ECP) in the treatment of chronic lung allograft dysfunction (CLAD): a prospective, multicentre, open-label, randomised controlled trial studying the addition of ECP to standard care in the treatment of bilateral lung transplant patients with CLAD (E-CLAD UK)

White, Michael, Goudie, Nicola, Bardgett, Michelle, Gennery, Andrew R, Bryant, Andrew, Bevin-Nicholls, Alex, Frisby, Laura, Exley, Catherine, Carby, Martin, Thompson, Richard, Santhanakrishnan, Karthik, Phillipson, Julia, Chadwick, Thomas, Lally, Joanne, Vale, Luke, Kershaw, Anneka, Smith, Hesther, Lordan, James L, Hancock, Helen, Russell, Sian, Parmar, Jasvir, Wason, James MS, Errington, Rebecca, Fisher, Andrew J

2024

Overview

BackgroundLong-term survival after lung transplantation is limited compared with other organ transplants. The main cause is development of progressive immune-mediated damage to the lung allograft. This damage, which can develop via multiple immune pathways, is captured under the umbrella term chronic lung allograft dysfunction (CLAD). Despite the availability of powerful immunosuppressive drugs, there are presently no treatments proven to reverse or reliably halt the loss of lung function caused by CLAD. The aim of the E-CLAD UK trial is to determine whether the addition of immunomodulatory therapy, in the form of extracorporeal photopheresis (ECP), to standard care is more efficacious at stabilising lung function in CLAD compared with standard care alone.Methods and analysisE-CLAD UK is a Phase II clinical trial of an investigational medicinal product (Methoxsalen) delivered to a buffy coat prepared via an enclosed ECP circuit. Target recruitment is 90 bilateral lung transplant patients identified as having CLAD and being treated at one of the five UK adult lung transplant centres. Participants will be randomised 1:1 to intervention plus standard of care, or standard of care alone. Intervention will comprise nine ECP cycles spread over 20 weeks, each course involving two treatments of ECP on consecutive days. All participants will be followed up for a period of 24 weeks.The primary outcome is lung function stabilisation derived from change in forced expiratory volume in one second and forced vital capacity at 12 and 24 weeks compared with baseline at study entry. Other parameters include change in exercise capacity, health-related quality of life and safety. A mechanistic study will seek to identify molecular or cellular markers linked to treatment response and qualitative interviews will explore patient experiences of CLAD and the ECP treatment.A patient and public advisory group is integral to the trial from design to implementation, developing material to support the consent process and interview materials.Ethics and disseminationThe East Midlands—Derby Research Ethics Committee has provided ethical approval (REC 22/EM/0218). Dissemination will be via publications, patient-friendly summaries and presentation at scientific meetings.Trial registration numberEudraCT number 2022-002659-20; ISRCTN 10615985.

• Publisher: British Thoracic Society,BMJ Publishing Group LTD,BMJ Publishing Group
• Subject: Adult / Allografts / Apheresis / Biomarkers / Blood / Clinical trials / Consent / Dyspnea / Female / Graft Rejection / health economist / Heart / Hospitals / Humans / Leukocytes / Life expectancy / Lung - physiopathology / Lung Transplantation / Lung transplants / Male / Methoxsalen - therapeutic use / Middle Aged / Multicenter Studies as Topic / Participation / Patients / Photodynamic therapy / Photopheresis - methods / Primary Graft Dysfunction - therapy / Prospective Studies / Quality of Life / Randomized Controlled Trials as Topic / Skin cancer / Spirometry / Stem cell transplantation / Treatment Outcome / United Kingdom